Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk’s Saxenda proven to offer benefits beyond weight loss

Novo Nordisk’s Saxenda proven to offer benefits beyond weight loss

19th May 2015

Novo Nordisk has reported clinical study data demonstrating the weight-loss-dependent and independent effects of its anti-obesity therapy Saxenda.

This was the first study to assess the degree to which the benefits of liraglutide could be assigned to the drug itself, rather than the effect of the weight loss.

A post-hoc analysis confirmed that weight loss has a positive impact on a number of cardiometabolic risk factors, including high blood pressure and cholesterol.

However, Professor Luc Van Gaal, head of the department of endocrinology, diabetology and metabolism at Antwerp University Hospital, added: "Importantly, we also saw the direct effect of liraglutide on glycaemic control and other endpoints, independent of weight loss."

Endpoints primarily driven by weight loss included waist circumference, blood pressure, cholesterol levels, sleep apnoea severity and the impact of weight on quality of life. However, the drug itself was mainly responsible for better glycaemic endpoints and a reduction in the use of oral antidiabetic treatments.

The company received European regulatory approval for the new obesity drug in March of this year.ADNFCR-8000103-ID-801787897-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.